vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and James River Group Holdings, Inc. (JRVR). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $167.7M, roughly 1.7× James River Group Holdings, Inc.). James River Group Holdings, Inc. runs the higher net margin — 19.1% vs -45.7%, a 64.8% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 32.4%). James River Group Holdings, Inc. produced more free cash flow last quarter ($-23.6M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -8.7%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.
GH vs JRVR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $167.7M |
| Net Profit | $-128.5M | $32.1M |
| Gross Margin | 64.6% | — |
| Operating Margin | -43.0% | 14.6% |
| Net Margin | -45.7% | 19.1% |
| Revenue YoY | 39.4% | 32.4% |
| Net Profit YoY | -15.8% | 149.5% |
| EPS (diluted) | $-1.01 | $0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $167.7M | ||
| Q3 25 | $265.2M | $172.7M | ||
| Q2 25 | $232.1M | $174.8M | ||
| Q1 25 | $203.5M | $172.3M | ||
| Q4 24 | $201.8M | $126.7M | ||
| Q3 24 | $191.5M | $191.5M | ||
| Q2 24 | $177.2M | $188.3M | ||
| Q1 24 | $168.5M | $201.1M |
| Q4 25 | $-128.5M | $32.1M | ||
| Q3 25 | $-92.7M | $1.0M | ||
| Q2 25 | $-99.9M | $4.8M | ||
| Q1 25 | $-95.2M | $9.6M | ||
| Q4 24 | $-111.0M | $-64.8M | ||
| Q3 24 | $-107.8M | $-39.4M | ||
| Q2 24 | $-102.6M | $7.6M | ||
| Q1 24 | $-115.0M | $15.4M |
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
| Q4 25 | -43.0% | 14.6% | ||
| Q3 25 | -37.3% | 1.5% | ||
| Q2 25 | -45.9% | 4.2% | ||
| Q1 25 | -54.6% | 9.3% | ||
| Q4 24 | -62.4% | -57.0% | ||
| Q3 24 | -61.3% | -27.1% | ||
| Q2 24 | -56.8% | 10.7% | ||
| Q1 24 | -59.2% | 16.4% |
| Q4 25 | -45.7% | 19.1% | ||
| Q3 25 | -35.0% | 0.6% | ||
| Q2 25 | -43.0% | 2.7% | ||
| Q1 25 | -46.8% | 5.6% | ||
| Q4 24 | -55.0% | -51.1% | ||
| Q3 24 | -56.3% | -20.6% | ||
| Q2 24 | -57.9% | 4.0% | ||
| Q1 24 | -68.2% | 7.7% |
| Q4 25 | $-1.01 | $0.59 | ||
| Q3 25 | $-0.74 | $-0.02 | ||
| Q2 25 | $-0.80 | $0.06 | ||
| Q1 25 | $-0.77 | $0.16 | ||
| Q4 24 | $-0.90 | $-2.44 | ||
| Q3 24 | $-0.88 | $-1.10 | ||
| Q2 24 | $-0.84 | $0.13 | ||
| Q1 24 | $-0.94 | $0.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $260.9M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $538.2M |
| Total Assets | $2.0B | $4.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $260.9M | ||
| Q3 25 | $580.0M | $238.8M | ||
| Q2 25 | $629.1M | $220.0M | ||
| Q1 25 | $698.6M | $279.4M | ||
| Q4 24 | $525.5M | $362.3M | ||
| Q3 24 | $585.0M | $359.8M | ||
| Q2 24 | $933.7M | $672.5M | ||
| Q1 24 | $1.0B | $305.5M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-99.3M | $538.2M | ||
| Q3 25 | $-354.5M | $503.6M | ||
| Q2 25 | $-305.5M | $492.6M | ||
| Q1 25 | $-250.8M | $484.5M | ||
| Q4 24 | $-139.6M | $460.9M | ||
| Q3 24 | $-60.1M | $530.3M | ||
| Q2 24 | $-1.6M | $541.8M | ||
| Q1 24 | $68.3M | $539.5M |
| Q4 25 | $2.0B | $4.9B | ||
| Q3 25 | $1.3B | $5.0B | ||
| Q2 25 | $1.3B | $5.0B | ||
| Q1 25 | $1.3B | $4.9B | ||
| Q4 24 | $1.5B | $5.0B | ||
| Q3 24 | $1.5B | $5.0B | ||
| Q2 24 | $1.6B | $4.7B | ||
| Q1 24 | $1.7B | $5.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $-18.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $-23.6M |
| FCF MarginFCF / Revenue | -19.3% | -14.1% |
| Capex IntensityCapex / Revenue | 9.9% | 2.9% |
| Cash ConversionOCF / Net Profit | — | -0.59× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $-17.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $-18.8M | ||
| Q3 25 | $-35.4M | $34.3M | ||
| Q2 25 | $-60.3M | $25.2M | ||
| Q1 25 | $-62.7M | $-51.5M | ||
| Q4 24 | $-64.5M | $-247.1M | ||
| Q3 24 | $-51.1M | $-269.9M | ||
| Q2 24 | $-94.0M | $-8.7M | ||
| Q1 24 | $-30.3M | $24.1M |
| Q4 25 | $-54.2M | $-23.6M | ||
| Q3 25 | $-45.8M | $33.7M | ||
| Q2 25 | $-65.9M | $24.7M | ||
| Q1 25 | $-67.1M | $-52.7M | ||
| Q4 24 | $-83.4M | $-252.0M | ||
| Q3 24 | $-55.3M | $-270.8M | ||
| Q2 24 | $-99.1M | $-9.3M | ||
| Q1 24 | $-37.2M | $23.3M |
| Q4 25 | -19.3% | -14.1% | ||
| Q3 25 | -17.3% | 19.5% | ||
| Q2 25 | -28.4% | 14.1% | ||
| Q1 25 | -33.0% | -30.6% | ||
| Q4 24 | -41.3% | -198.9% | ||
| Q3 24 | -28.9% | -141.4% | ||
| Q2 24 | -55.9% | -4.9% | ||
| Q1 24 | -22.1% | 11.6% |
| Q4 25 | 9.9% | 2.9% | ||
| Q3 25 | 3.9% | 0.4% | ||
| Q2 25 | 2.4% | 0.3% | ||
| Q1 25 | 2.2% | 0.7% | ||
| Q4 24 | 9.4% | 3.9% | ||
| Q3 24 | 2.2% | 0.4% | ||
| Q2 24 | 2.9% | 0.3% | ||
| Q1 24 | 4.1% | 0.4% |
| Q4 25 | — | -0.59× | ||
| Q3 25 | — | 33.61× | ||
| Q2 25 | — | 5.29× | ||
| Q1 25 | — | -5.38× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.14× | ||
| Q1 24 | — | 1.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
JRVR
| Excess And Surplus Lines | $156.7M | 93% |
| Specialty Admitted Insurance | $10.9M | 7% |
